Year None20242023202220212020201920182017 Dec 17, 2024 Tenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy Dec 16, 2024 Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024 Nov 25, 2024 Tenaya Therapeutics Doses First Patient in RIDGE™-1 Phase 1b Clinical Trial of TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy Nov 19, 2024 Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Nov 06, 2024 Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update Oct 17, 2024 Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM Sep 03, 2024 Tenaya Therapeutics to Participate in Upcoming Investment Conferences Aug 08, 2024 Tenaya Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update Jun 27, 2024 Tenaya Therapeutics Announces Research Leadership Updates Jun 18, 2024 Tenaya Therapeutics to Participate at the TD Cowen Genetic Medicines & RNA Summit Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 18
Dec 17, 2024 Tenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy
Dec 16, 2024 Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024
Nov 25, 2024 Tenaya Therapeutics Doses First Patient in RIDGE™-1 Phase 1b Clinical Trial of TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
Nov 06, 2024 Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Oct 17, 2024 Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM
Aug 08, 2024 Tenaya Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
